Pfizer

Actualités

Reuters - Il y a 8 heures

Canada approves Moderna's RSV vaccine for adults aged 60 and older

UPDATE 1-Canada approves Moderna's RSV vaccine for adults aged 60 and older Adds details and background in paragraphs 2-8 Nov 8 (Reuters) - Moderna MRNA.O said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years and older, making it the country's first authorised mRNA-based shot for the condition.

Reuters - Il y a 1 jour

Xanax maker Viatris beats quarterly estimates on demand for new generic drugs

Xanax maker Viatris beats quarterly estimates on demand for new generic drugs Nov 7 (Reuters) - Drugmaker Viatris VTRS.O beat Wall Street estimates for third-quarter profit and revenue on Thursday, helped by strong demand for its new generic asthma and ADHD drugs, among others, sending its shares up 2.5% premarket. Sales at Viatris' generic business have been boosted by new products such as Breyna, a cheaper version of AstraZeneca's AZN.L asthma inhaler Symbicort, and lisdexamfetamine, a generic

Reuters - Il y a 1 jour

Moderna reports surprise profit on higher-than-expected COVID vaccine sales

UPDATE 3-Moderna reports surprise profit on higher-than-expected COVID vaccine sales Shares up nearly 5% to $54.22 in early trading Spikevax COVID vaccine sales reached $1.8 billion, beating expectations Moderna expects lower COVID vaccine sales this year compared to 2023 $10 million in RSV vaccine sales far below Wall Street view Adds share move, paragraph 2, details from Moderna investor call in paragraphs 7, 9, 10 By Patrick Wingrove Nov 7 (Reuters) - Moderna MRNA.O reported a surprise third-

Reuters - Il y a 1 jour

Moderna reports surprise profit on higher-than-expected COVID vaccine sales

Moderna reports surprise profit on higher-than-expected COVID vaccine sales By Patrick Wingrove Nov 7 (Reuters) - Moderna MRNA.O reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new respiratory syncytial virus shot. The Cambridge, Massachusetts-based company posted a profit of $13 million, or 3 cents a share, for the quarter, compared to a loss of $3.6 billion a year ago.

Reuters - Il y a 2 jours

Abbott India posts Q2 profit rise on strong demand, price hikes

Abbott India posts Q2 profit rise on strong demand, price hikes Nov 7 (Reuters) - Drugmaker Abbott India ABOT.NS reported a rise in second-quarter profit on Thursday, helped by strong demand for its gastrointestinal and anti-infective medications. The company, which makes the antacid Digene, reported a profit of 3.59 billion rupees ($42.6 million) for the quarter ended Sept.

Reuters - Il y a 2 jours

U.S. STOCKS Cencora, Charles River, Howmet Aerospace

BUZZ-U.S. STOCKS ON THE MOVE-Cencora, Charles River, Howmet Aerospace Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes soared to record highs on Wednesday, as Republican Donald Trump won the 2024 U.S. presidential election in a remarkable comeback four years after he was voted out of the White House.

Reuters - Il y a 2 jours

US drugmakers muted after Trump's election victory

BUZZ-US drugmakers muted after Trump's election victory Updates ** U.S. drugmakers' shares trading up between 0.5% and 1% after Donald Trump elected as U.S. president ** Gilead GILD.O gains 1.4%, while Abbvie ABBV.N , Amgen AMGN.O Merck MRK.N , Bristol Myers BMY.N and J&J JNJ.N rise marginally ** Leerink analysts said they view Trump's win as mixed for large-cap biopharma since it creates potential uncertainty regarding U.S.

Reuters - Il y a 2 jours

Vaccine makers fall after Trump win

BUZZ-Vaccine makers fall after Trump win ** Shares of vaccine makers fall between 2% to 8% after Donald Trump is elected U.S. president for a second term ** Pfizer PFE.N down 2.4%, Moderna MRNA.O down 5%, Novavax NVAX.O down 7.7%, ** U.S.-listed shares of Sanofi SASY.PA , SNY.O and GSK GSK.L , GSK.N down 3.2% and 2.9% respectively ** Trump recently said he would let former presidential candidate and anti-vaccine advocate Robert F.

Reuters - Il y a 2 jours

US drugmakers rise as Trump wins second US presidential term

BUZZ-US drugmakers rise as Trump wins second US presidential term ** Shares of some U.S. drugmakers rise between 1% and 3% premarket as Donald Trump wins second term at the White House ** Eli Lilly LLY.N shares gain 2.8%, Abbvie ABBV.N up about 2%, Amgen AMGN.O shares rise 1.5%, and Merck MRK.N up 1.3% ** Gilead GILD.O gains 1.2%, while Pfizer PFE.N and Bristol Myers BMY.N inch up about 1% in premarket trading ** BMO Capital had said ahead of elections that a Trump victory would be "net positive

Reuters - Il y a 3 jours

Canada approves GSK's RSV vaccine for adults aged 50 to 59

Canada approves GSK's RSV vaccine for adults aged 50 to 59 Nov 5 (Reuters) - GSK GSK.L has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said on Tuesday, making it the country's first authorized RSV shot for that age group. The U.S. Centers for Disease Control and Prevention decided to hold off recommending the use of the vaccine, Arexvy, in adults under 60, despite the Food and Drug Administration approving it for that age group.

Reuters - Il y a 3 jours

Stocks to watch as White House race enters final stretch

UPDATE 1-Stocks to watch as White House race enters final stretch Recasts paragraph 1, changes dateline By Ankika Biswas, Pranav Kashyap Nov 5 (Reuters) - As Americans go to the polls to elect a new president , investors are trying to gauge how stock markets will react as polls and betting platforms point to a tight race between Vice President Kamala Harris and former President Donald Trump.

Reuters - Il y a 4 jours

Public funding for nature conservation stalls at COP16, eyes on private investment

UPDATE 1-Public funding for nature conservation stalls at COP16, eyes on private investment Rich countries did not respond to UN chief's demand for conservation donations Delegates hope revamping global financial system will generate cash for nature Countries reach deal on charging companies for genetic information use Updated to add comment from US State Department in paragraph 17 and AstraZeneca in paragraph 22 By Jake Spring CALI, Colombia, Nov 3 (Reuters) - Wealthy nations appeared to hit a

Reuters - Il y a 4 jours

AstraZeneca says experimental obesity pill safe in early-stage trial

UPDATE 4-AstraZeneca says experimental obesity pill safe in early-stage trial Updates shares in paragraph 3, adds details on other obesity drug data in paragraphs 12-15 By Maggie Fick LONDON, Nov 4 (Reuters) - AstraZeneca AZN.L said on Monday its experimental weight-loss pill, licensed a year ago from China's Eccogene for up to $2 billion, was safe and tolerable in an early-stage trial, with side effects consistent with the GLP-1 drug class.

Reuters - Il y a 4 jours

Viking slips as manufacturing concerns cloud promising oral obesity drug data

UPDATE 3-Viking slips as manufacturing concerns cloud promising oral obesity drug data Adds analyst comments in paragraphs 10-11 and market value details in paragraph 4; updates shares throughout By Sriparna Roy and Bhanvi Satija Nov 4 (Reuters) - Viking Therapeutics VKTX.O shares reversed course to fall 8% on Monday as focus shifted to the drug developer's ability to mass produce its oral obesity treatment that was shown to be safe and effective in a small trial.

Reuters - Il y a 4 jours

Viking Therapeutics soars as early-stage oral obesity drug data exceeds expectations

Viking Therapeutics soars as early-stage oral obesity drug data exceeds expectations Nov 4 (Reuters) - Viking Therapeutics VKTX.O shares surged 25% before the bell on Monday after early-stage data from the company's experimental oral obesity drug showed weight loss and safety above Wall Street expectations. Patients who received the higher dose 100 milligram version of the oral drug, VK2735, showed an 8.2% reduction in body weight on average after 28 days, compared to 1.4% for placebo.

Reuters - Il y a 4 jours

BioNTech lowers full-year revenue outlook on 19 seasonality, inventory write-downs

BioNTech lowers full-year revenue outlook on COVID-19 seasonality, inventory write-downs Nov 4 (Reuters) - German drugmaker BioNTech 22UAy.DE on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, inventory write-downs and Pfizer PFE.N charges. The company now expects 2024 revenue to be at the low end of the guidance range of 2.5 to 3.1 billion euros ($2.72 - $3.38 billion).

Reuters - Il y a 5 jours

Public funding for nature conservation stalls at COP16, eyes on private investment

Public funding for nature conservation stalls at COP16, eyes on private investment Rich countries did not respond to U.N. chief's demand for conservation donations Delegates hope revamping global financial system will generate cash for nature Countries reach deal on charging companies for genetic information use By Jake Spring CALI, Colombia, Nov 3 (Reuters) - Wealthy nations appeared to hit a limit with how much they are willing to pay to conserve nature around the world, instead shifting their

Reuters - Il y a 1 semaine

Stocks to watch as White House race enters final stretch

UPDATE 1-Stocks to watch as White House race enters final stretch Adds hyperlinks in paragraphs 4 and 32 By Ankika Biswas, Pranav Kashyap Nov 1 (Reuters) - Just days ahead of the Nov. 5 presidential election in the U.S., investors are trying to gauge how stock markets will react as polls and betting platforms point to a tight race between Vice President Kamala Harris and former President Donald Trump.

Reuters - Il y a 1 semaine

Harris vs Trump: Stocks to watch as White House race enters final stretch

Harris vs Trump: Stocks to watch as White House race enters final stretch By Ankika Biswas and Pranav Kashyap Nov 1 (Reuters) - Just days ahead of the Nov. 5 presidential election in the U.S., investors are trying to gauge how stock markets will react as polls and betting platforms point to a tight race between Vice President Kamala Harris and former President Donald Trump.

Reuters - Il y a 1 semaine

Drugmakers Apotex, Heritage to pay $49 mln to resolve states' price-fixing claims

Drugmakers Apotex, Heritage to pay $49 mln to resolve states' price-fixing claims By Mike Scarcella Oct 31 (Reuters) - Generic drugmakers Apotex and Heritage Pharmaceuticals have agreed to pay nearly $50 million to settle claims by Connecticut and other states that accused them of conspiring to artificially inflate prices. Heritage, a subsidiary of India’s Emcure Pharmaceuticals, and Apotex said they will cooperate with the states in continuing litigation against dozens of other drugmakers acc

Conditions

Actifs populaires

Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.

Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.

Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.

Pfizer

Actualités

Conditions

Actifs populaires

Chat en direct XM